Key result
Circulating GAS5 expression predicted recurrence after radiofrequency catheter ablation in patients with atrial fibrillation (HR 0.127; 95% CI 0.026-0.616; P=0.01).
Why the study?
Circulating long noncoding RNAs play a vital role in disease diagnosis and prognosis, but the role of GAS5 in atrial fibrillation remained to be evaluated.
Does circulating lncRNA GAS5 serve as a diagnostic and prognostic biomarker in patients with atrial fibrillation?
Observational (n=173)
Does circulating lncRNA GAS5 serve as a diagnostic and prognostic biomarker in patients with atrial fibrillation?
Circulating lncRNA GAS5 is a promising novel biomarker for the early diagnosis of atrial fibrillation and for predicting recurrence following radiofrequency catheter ablation.
BACKGROUND: Circulating long noncoding RNA (lncRNA) plays a vital role in clinical disease diagnosis and prognosis. Here, we evaluate the role of a lncRNA, named growth arrest specific 5 (GAS5), in atrial fibrillation (AF). METHODS: Expression of GAS5 was measured by qRT-PCR. Diagnostic and prognostic values of GAS5 were assessed by the receiver operating characteristics curve (ROC), Kaplan-Meier (KM) and Cox regression analyses. RESULTS: A total of 173 participants were enrolled in this study. Circulating GAS5 expression was significantly down-regulated in AF patients. This change occurred prior to enlargement of the left atrial volume and was strongly associated with AF progression, which demonstrates the potential use of GAS5 as an early biomarker. The area under the ROC curve (AUC) was 0.858 (95% CI 0.789-0.926, P < .001). Seventy of the 85 AF patients received radiofrequency catheter ablation (RFCA), and 22 (31.4%) had relapsed by the 1-year follow-up. The KM analysis (log-rank test, P = .031) and multivariable Cox analysis (HR = 0.127, 95% CI 0.026-0.616; P = .01) revealed that GAS5 has a role in predicting recurrence after RFCA. CONCLUSION: Circulating lncRNA GAS5 is a potential biomarker for AF diagnosis and prognosis. Down-regulation of GAS5 occurs prior to left atrial enlargement and can be used for the prognosis of AF progression and recurrence.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2020) conducted an observational in Atrial fibrillation (n=173). Circulating GAS5 expression was evaluated on Recurrence after radiofrequency catheter ablation (HR 0.127, 95% CI 0.026-0.616, p=.01). Circulating GAS5 expression predicted recurrence after radiofrequency catheter ablation in patients with atrial fibrillation (HR 0.127; 95% CI 0.026-0.616; P=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: